A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
TIME ·
The treatment is still experimental, but results from Moderna and Merck add scientific support for a vaccine-based approach to treating the cancer.
Publication and source information
- Platform
- NewsTiVi
- Source
- TIME
- Published
- 10/22/2026, 11:54:49 PM
- Country
- United States
The headline and summary are supplied by the publisher. Read the full report on the source website.
Contact: info@newstivi.com